Nonparametric Estimation from Incomplete Observations

Kaplan, Edward L.; Meier, Paul

doi:10.1007/978-1-4612-4380-9_25

Cited by 16,743 publications

(10,714 citation statements)

References 14 publications

Supporting

Mentioning

10,556

Contrasting

Unclassified

128

Order By: Relevance

“…Overall survival was computed from time-to-event data counting days from diagnosis to death (event) or to 31 August 2017 (censoring). Survival curves were constructed using the method of Kaplan and Meier [18]. Five-year survival was described as proportions with 95% confidence intervals (CI).…”

Section: Methodsmentioning

confidence: 99%

Oncological treatment and outcome of colorectal cancer in Greenland

Odgaard

Lohse

Petersen

et al. 2018

International Journal of Circumpolar Health

View full text Add to dashboard Cite

Oncological treatment of colorectal cancer (CRC) has been available in Greenland since 2004. Treatment is provided by Queen Ingrid´s Hospital (QIH), under supervision from the Department of Oncology, Rigshospitalet, Denmark. The study describes patient characteristics, oncological treatment and survival for the first 8 years of treatment. The study was a registry-based observational study of all patients in Greenland diagnosed with histologically verified CRC from August 2004 to August 2012. Analyses were stratified according to stage and discussed in relation to reported data from patients with CRC in Denmark. 180 patients were included. . Stage I, II, III, and IV comprised 15, 34, 23, and 23%, respectively. 5% presented with unknown stage. A total of 51% received oncological treatment. 79% of patients with Stage III disease received adjuvant chemotherapy, 61% of patients with metastatic CRC received palliative chemotherapy. Five-year survival was 48 and 53% for colon and rectum cancer, respectively. An insignificant trend towards higher survival in men than in women was seen; adjusted hazard ratio for death (women vs men) = 1.46 (95% CI = 0.97–2.19). In conclusion; Stage distribution, provision of oncological treatment and 5-year survival were comparable to patients diagnosed and treated in Denmark.

show abstract

Section: Methodsmentioning

confidence: 99%

Oncological treatment and outcome of colorectal cancer in Greenland

Odgaard

Lohse

Petersen

et al. 2018

International Journal of Circumpolar Health

View full text Add to dashboard Cite

show abstract

“…Disease-free survival was defi ned as the time between the date of ER and the last cancer-free followup evaluation or death. Overall survival, disease-free survival, and recurrence rates were analyzed with the Kaplan -Meier product limit method ( 36 ). Th e log-rank statistic was used to compare overall and cancer-free survival between SCC and AC of the esophagus.…”

Section: Resultsmentioning

confidence: 99%

Comparison of the Long-Term Outcomes of Endoscopic Resection for Superficial Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus in Japan

Nakagawa

Koike

Iijima

et al. 2014

American Journal of Gastroenterology

View full text Add to dashboard Cite

OBJECTIVES:Few studies have simultaneously evaluated the long-term outcomes of endoscopic resection (ER) for squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus in Japan. The objective of this study was to evaluate the long-term outcomes of ER for superfi cial esophageal cancer in consecutive patients. METHODS:This was a retrospective study from a single institution. From April 2001 to June 2012, 204 patients with SCC and 26 patients with AC were included from a total of 355 consecutive patients who were treated by esophageal ER at the Tohoku University Hospital. Patients with submucosal invasion deeper than 200 μ m and lymphovascular involvement were excluded. The intervention followed was endoscopic therapy. RESULTS:Overall survival, disease-free survival, and recurrence rates were evaluated as long-term outcomes. In the SCC group, during the median observation time of 36.5 months (range, 6 -120 months), 22 (10.8 % ) patients experienced metachronous recurrence, 4 (2.0 % ) patients experienced local recurrence, and 27 (13.2 % ) patients died from causes unrelated to SCC. In the AC group, during the median observation time of 45.5 months (range, 6 -131 months), one patient (3.8 % ) experienced metachronous recurrence and two (7.7 % ) died from causes unrelated to AC. The cumulative 5-year overall survival rates were not signifi cantly different between SCC (75.9 % ) and AC (88.9 % ) ( P = 0.120). The cumulative 5-year disease-free survival rates of SCC (57.1 % ) were signifi cantly lower than those of AC (85.2 % ; P = 0.017). The cumulative 5-year recurrence rates of SCC (32.0 % ) were signifi cantly higher than those of AC (4.2 % ; P = 0.023). CONCLUSIONS:The rate of recurrence after ER was higher in patients with SCC than that in patients with AC. These fi ndings suggest that, by detecting AC of the esophagus earlier, a satisfactory prognosis without recurrence can be expected after ER in Japan, and more rigorous endoscopic follow-up is necessary after ER in patients with SCC than in those with AC.

show abstract

“…Survival was calculated from initiation of treatment to the date of last contact or to the date of death. The Kaplan -Meier method was used to calculate TTP and survival curves (Kaplan and Meier, 1958). Data analysis was performed using the computerised statistical package SPSS version 10.0.…”

Section: Resultsmentioning

confidence: 99%

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

et al. 2004

View full text Add to dashboard Cite

Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m À2 and paclitaxel 150 mg m À2 , every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3 -4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmarplantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and welltolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS.

show abstract

Nonparametric Estimation from Incomplete Observations

Cited by 16,743 publications

References 14 publications

Oncological treatment and outcome of colorectal cancer in Greenland

Oncological treatment and outcome of colorectal cancer in Greenland

Comparison of the Long-Term Outcomes of Endoscopic Resection for Superficial Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus in Japan

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

Contact Info

Product

Resources

About